JP2014514275A - タンパク質ナノ粒子分散系 - Google Patents

タンパク質ナノ粒子分散系 Download PDF

Info

Publication number
JP2014514275A
JP2014514275A JP2013557933A JP2013557933A JP2014514275A JP 2014514275 A JP2014514275 A JP 2014514275A JP 2013557933 A JP2013557933 A JP 2013557933A JP 2013557933 A JP2013557933 A JP 2013557933A JP 2014514275 A JP2014514275 A JP 2014514275A
Authority
JP
Japan
Prior art keywords
dispersion
protein
crowder
nanoclusters
viscosity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013557933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014514275A5 (enExample
Inventor
ジョンストン，キース，ピー．
メイナード，ジェニファー，エー．
ミラー，アンドレア
ウィルソン，ブライアン
トラスケット，トーマス，エム．
ダイニン，アイリーン
ボーワンカー，アメヤ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2014514275A publication Critical patent/JP2014514275A/ja
Publication of JP2014514275A5 publication Critical patent/JP2014514275A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2013557933A 2011-03-10 2012-03-09 タンパク質ナノ粒子分散系 Pending JP2014514275A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161451571P 2011-03-10 2011-03-10
US61/451,571 2011-03-10
US201261587648P 2012-01-17 2012-01-17
US61/587,648 2012-01-17
PCT/US2012/028640 WO2012122544A2 (en) 2011-03-10 2012-03-09 Protein nanoparticle dispersions

Publications (2)

Publication Number Publication Date
JP2014514275A true JP2014514275A (ja) 2014-06-19
JP2014514275A5 JP2014514275A5 (enExample) 2015-04-23

Family

ID=46795761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013557933A Pending JP2014514275A (ja) 2011-03-10 2012-03-09 タンパク質ナノ粒子分散系

Country Status (6)

Country Link
US (1) US20120230913A1 (enExample)
EP (1) EP2683362A4 (enExample)
JP (1) JP2014514275A (enExample)
AU (1) AU2012225277A1 (enExample)
CA (1) CA2829629A1 (enExample)
WO (1) WO2012122544A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017104759A1 (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
JP2019530703A (ja) * 2016-10-06 2019-10-24 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
JP2020125363A (ja) * 2015-12-22 2020-08-20 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
US11554101B2 (en) 2014-06-24 2023-01-17 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US11737981B2 (en) 2017-09-12 2023-08-29 The Trustees Of Princeton University Cellulosic polymer nanoparticles and methods of forming them
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US12357582B2 (en) 2017-11-03 2025-07-15 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2170283T3 (en) 2007-06-22 2019-04-15 Univ Texas CREATION OF STABLE SUBMICRON Peptide OR PROTEIN PARTICLES BY THIN FILM FREEZING
US20110229957A1 (en) * 2010-03-17 2011-09-22 Lehigh University Polymer-mediated electromagnetic field-based particle concentrator
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP3613413A1 (en) 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US20130336957A1 (en) * 2012-05-21 2013-12-19 Abbvie, Inc. Novel purification of human, humanized, or chimeric antibodies using protein a affinity chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9677869B2 (en) 2012-12-05 2017-06-13 Perimeter Medical Imaging, Inc. System and method for generating a wide-field OCT image of a portion of a sample
CN103886226A (zh) * 2012-12-21 2014-06-25 中国科学院大连化学物理研究所 基于三维空间静电势重构的新型蛋白质粗粒化计算方法
CN103083659B (zh) * 2013-01-18 2015-05-13 北京华夏兴洋生物科技有限公司 新型无油佐剂制备方法及用途
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2796144A1 (en) 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
JP6213113B2 (ja) * 2013-09-30 2017-10-18 ブラザー工業株式会社 液体吐出記録装置及び液体回収方法
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP6338869B2 (ja) * 2014-01-28 2018-06-06 国立研究開発法人産業技術総合研究所 粒径分布計測方法
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
CN105031645B (zh) * 2015-07-09 2018-08-17 宁波荣安生物药业有限公司 一种人用狂犬病疫苗及其制备方法
JP6910029B2 (ja) * 2015-08-17 2021-07-28 国立研究開発法人科学技術振興機構 ナノクラスター分散液、ナノクラスター膜、ナノクラスター分散体、ナノクラスター分散液の製造方法およびナノクラスター分散液の製造装置
CN106492715B (zh) * 2016-12-19 2023-02-10 广东工业大学 一种制备微粒的方法及装置
WO2019018446A1 (en) 2017-07-17 2019-01-24 Fractal Heatsink Technologies, LLC SYSTEM AND METHOD FOR MULTI-FRACTAL THERMAL DISSIPATOR
EP3655748B1 (en) 2017-07-18 2023-08-09 Perimeter Medical Imaging, Inc. Sample container for stabilizing and aligning excised biological tissue samples for ex vivo analysis
KR101959812B1 (ko) * 2017-09-01 2019-03-19 성균관대학교 산학협력단 유기 발광 소자
WO2019191531A1 (en) 2018-03-30 2019-10-03 Idexx Laboratories, Inc. Quality control for point-of-care diagnostic systems
US12036280B2 (en) * 2018-11-21 2024-07-16 Regeneron Pharmaceuticals, Inc. High concentration protein formulation
US20210386680A1 (en) * 2018-12-06 2021-12-16 Board Of Regents, The University Of Texas System Selectively cleavable therapeutic nanoparticles
CN110823820A (zh) * 2019-10-17 2020-02-21 浙江工业大学 用于cod测量中的浊度干扰消除方法
CN111665217A (zh) * 2020-06-09 2020-09-15 吉林省农业科学院 一种大豆种子蔗糖含量的近红外光谱检测方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899897A (ja) * 1994-08-05 1996-04-16 Shionogi & Co Ltd インターロイキン−２吸着型脂質小球体
JP2007517023A (ja) * 2003-12-24 2007-06-28 サムヤン コーポレイション 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
WO2010009146A1 (en) * 2008-07-15 2010-01-21 University Of Kansas Nanoclusters for delivery of poorly water soluble drug nanoparticles
WO2010056657A2 (en) * 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
WO2010139442A1 (en) * 2009-06-05 2010-12-09 Chiesi Farmaceutici S.P.A. Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
AU2003291527A1 (en) * 2002-12-31 2004-07-29 Nektar Therapeutics Antibody-containing particles and compositions
EP1968550A2 (en) * 2005-12-16 2008-09-17 University Of Kansas Nanoclusters for delivery of therapeutics
WO2007072982A1 (en) * 2005-12-20 2007-06-28 Fujifilm Corporation Protein nanoparticles and the use of the same
JP2009173610A (ja) * 2008-01-28 2009-08-06 Fujifilm Corp タンパク質ナノ粒子
AU2009244742B2 (en) * 2008-05-09 2014-11-06 South Dakota State University Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0899897A (ja) * 1994-08-05 1996-04-16 Shionogi & Co Ltd インターロイキン−２吸着型脂質小球体
JP2007517023A (ja) * 2003-12-24 2007-06-28 サムヤン コーポレイション 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
WO2010009146A1 (en) * 2008-07-15 2010-01-21 University Of Kansas Nanoclusters for delivery of poorly water soluble drug nanoparticles
WO2010056657A2 (en) * 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
WO2010139442A1 (en) * 2009-06-05 2010-12-09 Chiesi Farmaceutici S.P.A. Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554101B2 (en) 2014-06-24 2023-01-17 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2017104759A1 (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
JP2017110001A (ja) * 2015-12-16 2017-06-22 株式会社 資生堂 タブレット型凍結乾燥化粧料
JP2020125363A (ja) * 2015-12-22 2020-08-20 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
US11103461B2 (en) 2015-12-22 2021-08-31 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
JP2022160693A (ja) * 2015-12-22 2022-10-19 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティ 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
JP2019530703A (ja) * 2016-10-06 2019-10-24 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
JP7275027B2 (ja) 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
US11737981B2 (en) 2017-09-12 2023-08-29 The Trustees Of Princeton University Cellulosic polymer nanoparticles and methods of forming them
US12357582B2 (en) 2017-11-03 2025-07-15 The Trustees Of Princeton University Hydrophobic ion pairing and flash nanoprecipitation for formation of controlled-release nanocarrier formulations
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation

Also Published As

Publication number Publication date
AU2012225277A1 (en) 2013-09-26
WO2012122544A2 (en) 2012-09-13
CA2829629A1 (en) 2012-09-13
EP2683362A2 (en) 2014-01-15
US20120230913A1 (en) 2012-09-13
EP2683362A4 (en) 2014-09-17
WO2012122544A3 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
JP2014514275A (ja) タンパク質ナノ粒子分散系
Ma et al. Overcoming multidrug resistance through the GLUT1-mediated and enzyme-triggered mitochondrial targeting conjugate with redox-sensitive paclitaxel release
KR102109053B1 (ko) 안정한 수성 항체 제제
CN114514035A (zh) 递送用于治疗疾病的治疗性生物制剂的组合物和方法
JP2010509243A (ja) 薬物動態学的および薬力学的特性を保持するタンパク質マイクロスフェア
US11945892B2 (en) Polymer excipients for biopharmaceutical formulations
JP2013144715A (ja) 生物医薬品製剤のための緩衝剤
JP7710485B2 (ja) 抗Ｈｅｒ２抗体薬物コンジュゲートの製剤
RS56362B1 (sr) Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
JP2023506629A (ja) 安定した抗ｐｄ－１抗体の薬剤学的製剤
TW202310873A (zh) 含有抗人類ｔｓｌｐ受體抗體之醫藥組成物
CN107837389A (zh) 用于抑制可溶生物分子的生物活性的组合物以及方法
EP3060256B1 (en) A novel stable formulation
US20240252596A1 (en) Injectable Polymeric Biopharmaceutical Formulations
Xu et al. Stability of intravenous antibody dilutions in clinical use: Differences across patient populations with varying body weights
CN116077646A (zh) 一种抗冠状病毒s蛋白的抗体制剂及其制备方法和用途
Krieg Development, characterization and stability of therapeutic protein co-formulations
Chi et al. Polydopamine-based Nanoadjuvants Promote a Positive Feedback Loop for Cancer Immunotherapy via Overcoming Photothermally Boosted T Cell Exhaustion
Dinin The manufacture and characterization of protein nanoclusters
Shen et al. Interfacial molecular engineering-driven self-emulsification: a green strategy for surfactant-free, high-efficiency oral delivery of cyclosporine A
WO2021231316A1 (en) Il-2 fusion polypeptide compositions and methods of making and using the same
Abraham Effects of Beta Cyclodextrin and Pluronic F-127 on the stability of model proteins: Lysozyme, Insulin and Antibodies
JP2023526024A (ja) Ｉｌ－２融合ポリペプチド組成物ならびにその作製及び使用方法
CN117731771A (zh) 液体抗体组合物及其应用
CN117355321A (zh) 增强性能的赋形剂以及降低生物制剂的粘度和提高生物制剂的稳定性的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160726

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161213